NOVOLOG MIX 70/30
NOVOLOG MIX 70/30 is an insulin analog indicated to improve glycemic control in adult patients with diabetes mellitus. The product is a fixed-ratio mixture containing insulin aspart protamine, an intermediate-acting insulin, and insulin aspart, a rapid-acting insulin. Due to these fixed proportions, the medication does not allow for separate basal and prandial dose adjustments and is not recommended for the treatment of diabetic ketoacidosis.
How NOVOLOG MIX 70/30 Works
This medication regulates glucose metabolism by lowering blood glucose levels through multiple biological pathways. It stimulates peripheral glucose uptake, particularly in skeletal muscle and fat, and inhibits the production of glucose by the liver. Furthermore, the drug enhances protein synthesis while simultaneously inhibiting the processes of lipolysis and proteolysis.
Details
- Status
- Prescription
- First Approved
- 2001-11-01
- Routes
- SUBCUTANEOUS
- Dosage Forms
- INJECTABLE
Companies
NOVOLOG MIX 70/30 Approval History
What NOVOLOG MIX 70/30 Treats
1 indicationsNOVOLOG MIX 70/30 is approved for 1 conditions since its original approval in 2001. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Diabetes
Drugs Similar to NOVOLOG MIX 70/30
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
NOVOLOG MIX 70/30 FDA Label Details
ProIndications & Usage
FDA Label (PDF)NOVOLOG MIX 70/30 is a mixture of insulin aspart protamine and insulin aspart indicated to improve glycemic control in adult patients with diabetes mellitus. Limitations of Use: • NOVOLOG MIX 70/30 is not recommended for the treatment of diabetic ketoacidosis. • The proportions of rapid-acting and long-acting insulins in NOVOLOG MIX 70/30 are fixed and do not allow for basal versus prandial dose adjustments. NOVOLOG MIX 70/30 is a mixture of insulin aspart protamine, an intermediate-acting human insulin analog, and insulin aspart, a rapid-acting human insulin analog, indicated to improve glyce...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.